Top 10 enterprise analysis of consistency evaluation, Qilu leading, Tianqing, Huahai

The consistency evaluation of foreword has gained a lot since the implementation of the policy! Most of the pillar varieties of enterprises have passed the evaluation or entered the application stage, and the quality of domestic imitated varieties is increasing Although a pharmaceutical tycoon recently announced that he would cut off most of the generic pharmaceutical business, and the industry also put forward some discussions on imitation and innovation, it has to be admitted that China has not really crossed the threshold of new drugs, and the status of generic drugs in China will remain unshakable for a short time, and then the work of consistency evaluation will inevitably continue This manuscript is to count the top 10 enterprises that have passed the consistency evaluation in China, and to observe the generic business of these enterprises can also reverse the status of generic drugs in China 1 Top 10 enterprises in consistency evaluation According to the data query of pharmaceutical intelligence, the top 10 enterprises that have passed the consistency evaluation are Qilu pharmaceutical, Zhengda Tianqing, Zhejiang Huahai, Sichuan Kelun, Shiyao Ouyi, Jiangsu Haosen, Jiangsu Hengrui, Shenzhen xinlitai, Chongqing Yaoyou, and Zhejiang Jingxin Among them, Qilu pharmaceutical has 30 declared varieties and 13 passed the evaluation, all of which are in the lead Zhengda Tianqing has applied for the approval There are 20 varieties reported, 11 passed, the passing rate is relatively high; there are 18 varieties reported by Zhejiang Huahai, 11 passed, the passing rate is relatively high See the figure below for details Qilu leads the way, followed by Tianqing & Huahai! As mentioned above, Qilu pharmaceutical is in the first place in terms of variety declaration or quantity passed; the first variety passed the consistency evaluation is gefitinib tablets (the supplementary application approval document for consistency evaluation was obtained on December 2017); subsequently, Qilu pharmaceutical varieties tenofovir dipivoxil fumarate tablets, terbinafine hydrochloride tablets, solina succinate new tablets, olanzapine tablets, olanzapine orally disintegrating tablets , levocetirizine hydrochloride tablets, ondansetron hydrochloride tablets, risperidone tablets, trimetazidine hydrochloride tablets, tegio capsules, adefovir dipivoxil tablets and warfarin sodium tablets all passed the consistency evaluation PS: according to the company's official website, lenalidomide capsules, risperidone orally disintegrating tablets and trimetazidine hydrochloride sustained-release tablets of Qilu pharmaceutical have passed the consistency evaluation Up to now, 12 varieties are the first in China and 6 varieties are exclusive And obviously including large varieties Photo source: http://www.qilu-pharma.com/product/100.html Zhengda Tianqing, the first variety to pass the consistency evaluation is tenofovir fumarate dipivoxil tablets (December 2017), the first declared variety is entecavir dispersible tablets (the second approved variety of the company), all of which are antiviral; later, metformin hydrochloride sustained-release tablets, imatinib mesylate capsules, alisentan tablets, gefitinib tablets, apixaban tablets, abit acetate Longpian, rivaroxaban, etc., passed / deemed to pass one after another Photo source: https://www.cttq.com/product/bingdu-detail-24068.htm Zhejiang Huahai, the first variety that passed the consistency evaluation was losartan potassium tablets (December 2017), and the first declared variety was irbesartan hydrochlorothiazide tablets (August 2017); then, irbesartan tablets, fosinopril sodium tablets, voriconazole tablets, donepezil hydrochloride tablets, valsartan tablets, risperidone tablets, nevirapine tablets, paroxetine hydrochloride tablets, lisinopril tablets passed one after another Photo source: https://www.huaaipharm.com/zjcp/info.aspx? Itemid = 613 3 Hengrui & hausen & Shiyao & Kelun ~ steady ahead! Hengrui, hausen, Shiyao and Kelun can be regarded as the first echelon of domestic pharmaceutical R & D strength, with the ability of imitation and innovation ranking first According to the statistics of the number of declared varieties, they are Kelun (26 varieties), Hengrui (21 varieties), Shiyao (20 varieties) and hausen; while according to the statistics of the number of varieties, they are Kelun (9 varieties), Shiyao (9 varieties), hausen (8 varieties) and Hengrui (7 varieties); for the above enterprises, the industry has a relatively calm attitude towards their product output, after all, the enterprises The industry is large enough Hengrui / hausen / Shiyao / Kelun, the varieties that pass the consistency evaluation for the first time are shown in the following figure Photo source: https://www.hrs.com.cn/productlist/0/3.html http://www.hansoh.cn/product/14958.htmhttp://www.e-cspc.com/index/cat/content/id/521.html http://www.kelun.com/product/71.html 4 Xinlitai & Yaoyou & Jingxin ~ outstanding! At present, the last three of the top 10 varieties are Shenzhen xinlitai (7 varieties passed), Chongqing Yaoyou (7 varieties passed) and Zhejiang Jingxin (6 varieties passed) For the first time, Shenzhen xinlitai has passed the product clopidogrel bisulfate, which is the pillar product of the product Xinlitai is well-known in China because of the product The recent 4 + 7 policy also caused uncertainty in the future trend of the product After the first variety passed, tegrilol tablets, desloratadine tablets, benazepril hydrochloride tablets, levetiracetam sustained-release tablets, pivastatin calcium tablets and olmesartan ester tablets all passed / deemed to pass the evaluation Photo source: http://www.salubris.com/cpzx/list  oneid 3.html Chongqing Yaoyou, the first product to pass the consistency evaluation is alfacalcohol tablets; after that, the company's clindamycin hydrochloride capsules, amlodipine besylate tablets, potassium chloride granules, indapamide tablets, entecavir tablets, venlafaxine hydrochloride tablets all passed / deemed to pass the evaluation Photo source: http://www.yaopharma.com/item/1382.aspx Zhejiang Jingxin, the first variety that passed the consistency evaluation was rosuvastatin calcium tablet, which is also a large variety; later, the company's simvastatin tablet, amlodipine besylate tablet, cefuroxime ester tablet, sertraline hydrochloride tablet and levetiracetam tablet all passed the evaluation Photo source: http://www.jingxinpharm.com/index.php/product/productlist/2/42.html 5 To sum up, the consistency evaluation of generic drugs in China has achieved a lot, and the improvement of generic drug quality is beyond doubt Although enterprises have paid a lot, it is a necessary way To some extent, top 10 enterprises represent the level of domestic drug R & D, but it can also be seen that some state-owned enterprises that people are often proud of are not on the list, and the future market distribution will be guided by "technology + capital" As for the status of generic drugs in China, whether it's consistency evaluation, or "4 + 7", or recent discussions on whether to cut off the generic business, they all prove the importance of the quality of generic drugs to a certain extent, remind the cost attribute of generic drugs, and guide the enterprises how to do generic drugs to a certain extent! Listen to the white statement: this point of view only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.